High res bio business network 2010 brochure

Creating Value-Generating Partnerships, Strengthening Relationships And Growing PipelinesPipelinesPipelines

+44 (0) 207 368 9465 [email protected] www.biobusinessnetwork.com

Book early

and save up to

£200TopSpeakers

Sponsored By: Organised By:Supported by:

� An exclusive, niche forum for decision-makers from biotech and pharmaceutical companies

� Over 900 1-2-1 meetings give you and your colleagues the opportunity to initiate deals and develop successful partnerships

� First-hand case studies on the latest deals including the Roche / Galapagos alliance and the AstraZeneca / Novexel acquisition

� Over 10 hours of networking built into the programme: make new contacts and build new relationships

� Be a part of the Biotech Investment Challenge: attract new partners and hear live feedbackfrom our line-up of pharma experts

Gary Buell, Head of Search and Evaluation, Merck Serono

Louk Pechtold, Director Business Development,Roche

Onno van de Stolpe, CEO, Galapagos

Marianne De Backer, Director Technology Licensing,Johnson & Johnson

Peter Luke, Senior Director Strategic Alliances, Pfizer

Vincent Mutel, CEO, Addex Pharmaceuticals

Roel Bulthuis,Head of Merck Serono Ventures,Merck Serono

Carlos de Sousa, Vice-President Corporate Licensing, Nycomed

Graziano Seghezzi, Partner, Sofinnova Partners

Kees Been, CEO, Envivo Pharma

Denise Goode, Executive Transaction Director, Strategic Planning and Business Development, AstraZeneca

Iain Buchanan, CEO, Novexel

Lubor Gaal, Director, External Science Technology & Licensing, Bristol Myers-Squibb

BACK BY POPULAR DEMAND!

The Most Productive Conference For Partnering Meetings And High-Level Networking

29th – 30th September 2010 Intercontinental Hotel, Geneva

“ The size and exclusivity of the audience make it an

extremely productive bio-partnering event ”

Margaret Beer, Senior Director and Head of Licensing and External Research, Merck & Co

6133 AW.indd 2 28/05/2010 16:44

The Most Productive Conference For 1-2-1 MeetingsAt no event will you have as many productive and meaningful 1-2-1 meetings with potential partners. Why? Quite simple. Our audience has a unique pharma-biotech split, a complete focus on business development and licensing and is almost exclusively limited to top decision-makers, positioning BioBusiness Network as the conference of choice for deal-makers.

� C-level ............................................................24%

� VP ......................................................................56%

� Director .........................................................14%

� Other .................................................................6%

Seniority

� Pharma ..........................................................47%

� Biotech ..........................................................48%

� Other .................................................................5%

Industry

� Business Development and Licensing ............................................88%

� Alliance Management ............................8%

� Other .................................................................4%

Function

Ensuring BioBusiness Network is produced for the industry, by the industry

Kees BeenCEOEnvivo Pharma

Dr. Christoph HuelsVice President Early Stage Licensing Merck Serono

Onno van de StolpeCEOGalapagos

Carlos de SousaVice-President Corporate LicensingNycomed

Dr Manfred HorstDirector Scienti� c Liaison, France and GermanyMerck and Co

“ I attend many conferences in my role at GSK but I certainly found this event to be

of a very high quality and very useful ”Kate Burt

Director Alliances and Transactions, GSK

Ensuring BioBusiness Network is produced for the industry, by the industryThe BioBusiness Network 2010 Advisory Board

Dear Colleague

As the BioBusiness Network Advisory Board, we are delighted to

invite you to join us at BioBusiness Network 2010 on 29th and 30th

September 2010 in Geneva.

This year, we are pleased to bring you an even more focused

programme that has been designed to give you senior-level

networking, high-quality partnering meetings and top level

insight over two value-packed days.

BioBusiness Network 2010 will be your � rst opportunity after the

summer to catch up on the latest partnering opportunities,

hear about market developments and meet the leading

decision-makers in the market. This year’s event is � rmly

cemented as THE place to make critical contacts and further your

pipelines. With the latest deal-case studies and cutting-edge

market information from leading big pharma and biotechs,

you can be sure you’ll leave the event with contacts you need to

achieve strategic growth through partnerships.

In the conference sessions, you will hear from more senior

speakers than ever before including pharma experts from Roche,

Merck Serono, Johnson & Johnson, Bristol Myers Squibb and

AstraZeneca. Plus, you will learn from the most innovative biotechs

from Novexel, Alligator BioScience, Intercell, Lectus Therapeutics

and more!

This is a unique opportunity to meet, network with and learn

from your peers, competitors and partners in an increasingly

competitive market. Make sure you register today to:

• Receive updates fi rst-hand on the biggest and highest-

pro� le deals

• Evaluate your � nancing options in a challenging funding

environment

• Benefi t from one-to-one meetings to capitalise on niche, high-

margin opportunities with the industry’s movers and shakers

• Take part in the BioBusiness Investment Challenge and

showcase your business amongst the very best

I look forward to meeting you in Geneva.

Best regards

Christoph Huels, PhDMember of the Advisory Board for BioBusiness Network 2010

Head of Early Stage Licensing, Merck Serono

The Most Productive Conference For Dear Colleague


29th – 30th September 2010, Intercontinental Hotel, Geneva

6133 AW.indd 3 28/05/2010 16:45

Make The Most Out Of Your Two Days At BioBusiness Network

BioBusiness Network isn’t focused on being the biggest bio-partnering event. (After all, how many people can you realistically meet over two days?) What we do guarantee you is high-quality networking and face-to-face time with all the people you want to meet. We deliberately cap the number of attendees at BioBusiness Network to ensure the event remains intimate and e� ective for networking. No one wants to spend their days � ghting through crowds of irrelevant people and BioBusiness Network cuts them out to help you ensure all your conversations have a focused business goal in mind.

The BioBusiness Network 2010 Promise

If your goal is the present your organisation as a ‘partner of choice’, BioBusiness Network has been designed to help you. Our event partners are ensured branding on our emails, brochures and letters as well as throughout the conference itself. If you want to raise your pro� le and get your message across to this year’s attendees, there are limited opportunities available for you to join the conference programme – by speaking on the agenda or joining a panel discussion.

For more details, contact Noj Mather at [email protected] or call +44 (0)20 7368 9555.

Boehringer Ingelheim • Apex Healthcare Consulting • TVM Capital • Evaluate Pharma • VenTech • Capital Royalty LP • BTG • Wyeth • Taylor Wessing • Roche • Caprotech Bioanalytics • Solvay Pharmaceuticals • UKTI • Czech Invest • Lovells • Avercia • Novartis • Fulcrum Pharma • Novozymes • Index Ventures • Astellas Pharma

Increase Your Exposure At BioBusiness Network: The Leading Platform To Meet Your Business Development Objectives

Past Sponsors Include:

Our cutting-edge partnering software guarantees you make full use of your time on site. You can:

• Upload a personalised company profi le giving you immediate stand-out

• Identify the precise partnering opportunities that meet your corporate objectives

• Browse all attendee pro� les to select your meeting partners based on your business needs

• Get up-to-date information about your partners’ current projects and opportunities

• Line-up your meetings ahead of the conference

One-To-One Partnering MeetingsWe know you come to the event � rst and foremost to connect with your peers so we have done everything possible to enhance the networking experience.

BioBusiness Network 2010 brings you even more e� ective networking. Our attendees come back year after year because they know they’ll have more opportunities to have quality face-to-face time with senior-level partners than anywhere else.

With structured networking throughout the programme as well as time for more informal networking, we give you every opportunity to spend time with the people you want to meet.

Unrivalled Networking

The BioBusiness Network conference programme features the most senior speaker line-up in Europe. Where else could you hear from (and meet with) decision-makers from top 10 pharma as well as the leading biotech companies?

We control the content of the BioBusiness agenda to ensure it add maximum value to your time at the conference. With high-level panel discussions, case studies and insights, you’ll have to plan your networking carefully to take it all in!

BioBusiness Network 2010: where the future of bio-partnering in shaped

In-Depth Conference ProgrammeWe’re now taking applications for the Investment Challenge – where biotechs are o� ered the opportunity to pitch big pharma investors live on stage – and to get open and honest feedback on their performance. Gain invaluable insight into what sparks the interest of potential partners and investors.

For the � rst time, the Investment Challenge presents categories in six key therapeutic areas.

To apply for a place, email [email protected] with a 250-word company overview. Successful candidates will be informed by 31st August 2010.

Take The Investment Challenge

The most e� ective way to increase the pro� le of your business is to take a Company Pro� le which will be available for the � rst time online, as well as in the conference documentation pack.

On-line

A company pro� le on the website is the most e� ective way to promote your brand and will give you immediate exposure to the entire bio-partnering community. The earlier you take a Company Pro� le, the more exposure you will receive.

Documentation Pack

In addition, a company pro� le will give you a full page in the conference documentation pack and is a superb way to increase your exposure – use it to promote your business or detail your current plans.

Take A Company Pro� le And Promote Your BrandOnce you have signed up to attend the conference, join our LinkedIn group to network with your peers ahead of the conference. Find out who else will be going, connect with potential partners and set up meetings around the event.

In addition you can engage in lively discussion and debate on the issues and challenges facing you today.

Search on LinkedIn for “The European BioBusiness Networking Community” and link up with your peers as soon as you register!

Online Networking

Make The Most Out Of Your Two Days At BioBusiness Network



6133 AW.indd 4 28/05/2010 16:45

12.00 – 17.00 One-to-One Partnering Meetings

One-to-One partnering meetings will run alongside the conference sessions. Choose which conference sessions you would like to attend and build your personalised meeting agenda around your availability accordingly.

08.00 Registration and Co� ee

08.40 Chairman’s Welcome

08.50 10 Minute Master Class – Networking In A Nutshell Christopher Barrat, Director, Greystone Partnership

You all come to BioBusiness Network to do just that – to network. But are you doing this as e� ectively as you can? In this ten minute session, you will learn cutting-edge techniques to improve how you network and truly make the most out of your two days at BioBusiness Network 2010.

09.00 Case-Study: Roche-Galapagos COPD Alliance – €400 Million Risk Sharing In Target Discovery To Product

Louk Pechtold, Director Business Development, Roche Onno van de Stolpe. CEO, Galapagos

• Unique target discovery platform of Galapagos and the basis of the alliance• How Alliance covers both small molecules and antibody targets• An overview of how Galapagos runs programmes in small molecules through to clinic• Risk based alliance: success based milestones and royalties for Galapagos, option to license for Roche• A prime example of how biotech–pharma deals are changing from contract research and in-licensing to

risk sharing in combination with opt-in

09.30 Panel Discussion: Big Pharma Outlook To 2015 – Key Strategies To Achieve Growth

Denise Goode, Executive Transaction Director – Strategic Planning and Business Development, AstraZeneca

Gary Buell, Head of Search and Evaluation, Early Stage Licensing, Merck Serono

Lubor Gaal, Head of Europe, Global Search, Strategic Transactions Group, Bristol Myers Squibb

Marianne De Backer, Director Technology Licensing, Johnson & Johnson• Assessing the M&A landscape: how is the pharma world changing?• Analysing Big Pharma’s current business model and the mergers, acquisitions and divestments that have

shaped the industry• What are the blockbuster drugs for the next fi ve years?• Is business development a major contributor to future growth in a tough market?• Opportunities and prospects in 2011

10.00 Speed Networking – Pre-Partnering Meeting Warm-Up!Introducing the fastest and most e� ective way to meet the delegate audience! In just thirty minutes you will have the opportunity to meet and exchange business cards with everyone in the room!

10.30 Morning Co� ee

11.00 Living Science, Transforming Lives Dr. Christoph Huels - Vice President Early Stage Licensing, Merck Serono

• An overview of Merck Serono company activities• Assessing the company’s approach to innovation and collaboration models• Key interests for collaboration with external partners

11.30 Case Study: Elan Drug Technologies-Acorda Therapeutics Ampyra Licensing And Development Partnership – The Concept, The Technology, The Launch, The Potential Blockbuster

Noeleen Kenny, VP Commercial Management and Dr Sarah Carty, Director, Business Development, Elan Drug Technologies • Early work in 1990’s in Elan on molecule• Acorda’s involvement - history of alliances between Elan and Acorda from 1997 to present • The challenge of 4-AP and the formulation and process approach taken by Elan Drug Technologies• The MXDAS™ technology, the clinical programme undertaken by Acorda and the launch in 2010 of

Ampyra™ (dalfampridine)• Attributes of a successful business partnership and lessons learned

12.00 Biotech CEO Panel: Key Trends And The Biotech Vision For 2011 – Securing Deals And Progressing Projects

Francois Curtin, CEO, Geneuro

Alux Wu, CEO, Crown Biosciences

Roland Kozlowski, CEO, Lectus Therapeutics

Rainer Lichtenberger, CEO, CEVEC Pharmaceuticals• Will biotechs continue to play the role of chief innovator?• The increase in virtualisation: what do biotechs need to do to stay ahead?• How can biotech companies maintain a competitive edge in a challenging market?• Exploring alternative funding strategies to secure deals and progress projects

12.30 The Perfect Pitch: Biotech Investment ChallengeIn this innovative session, 6 Biotechs all focused on diff erent therapeutic areas, will be given the opportunity to present their “perfect pitch” to our audience of potential partners and investors as well as to our panel of experts. Each Biotech will give a 10 minute company presentation highlighting their current projects. Then our panellists, consisting of big Pharma, VCs and Investment Banks will give their feedback on the strengths of the pitches just heard- highlighting the portions of the presentations that piqued their interest. This will not only give the presenting companies the platform to attract new partners, but will also give the presenting companies, and audience alike, insight into what sparks the interest of potential partners and investors. This session is a must attend for Pharma, Biotechs, and the investment community. The panellists will then have a chance to confer and choose “the perfect pitch” which will be presented a BioBusiness Network Award

Contact Michaela Menezes on [email protected] to � nd out more and join this exciting challenge.• Biotech #1 presentation (Oncology)• Biotech #2 presentation (CNS & Psychiatry)• Biotech #3 presentation (Cardiovascular)• Biotech #4 presentation (Diabetes/Metabolic)• Biotech #5 presentation (Infectious Disease)• Biotech #6 presentation (Auto-Immune (HIV))

13.30 Networking Lunch

14.30 Mastering The Art Of A Winning Pitch: Achieve A Competitive Edge And Secure Funding

Christopher Barrat, Director, Greystone Partnership• What are pharma companies looking for from your pitch?• What constitutes a perfect pitch – from content to delivery?• Delivering a fi rst class pitch – dos and don’ts• Improving your communication style to align with Big Pharma• Positioning your product heads and shoulders above the competition

15.00 Early Partnering Case Study: GSK / Astex – Building A Unique Strategic Drug Discovery Alliance

Jeremy Carmichael, Head of Business Development, Astex and leading representative, GSK • Indentifying the drivers that led to the early-stage deal• An overview of the GSK model and the basis of the GSK / Astex collaboration• Outlining the alternatives to an option-based deal• Key steps to progressing the partnership within predefi ned parameters

15.30 Afternoon Tea

16.00 Case Study: An Allosteric Odyssey: Partnering The MGluRs

Vincent Mutel, PhD, CEO and Co-Founder, Addex Pharmaceuticals• Historical overview of the industry’s work on mGluRs• An overview of the Addex contribution• Exploring the Addex partnerships• Other partnerships on mGluRs• Drug-candidates targeting mGluRs in development

16.30 Improving Corporate Social Responsibility Via Public-Private Partnerships In Neglected Diseases

Prof. Patrick Nef, CBO, Medicines for Malaria Ventures (MMV)• What socially responsible licensing means• How to ensure the dissemination of safe, effi cacious and aff ordable treatments for

developing countries • The product-development public-private partnership model for a global health impact• The MMV partnering and funding strategies to defeat malaria: 10 years of success/impact

17.00 Round-Table Discussions18.00 Drinks Reception19.00 Networking Dinner

(For details visit, www.biobusinessnetwork.com)

MAIN CONFERENCE DAY ONE 29th September 201008.00 Registration and Co� ee

MAIN CONFERENCE DAY ONE MAIN CONFERENCE DAY ONE MAIN CONFERENCE DAY ONE MAIN CONFERENCE DAY ONE 29th September 201029th September 2010



6133 AW.indd 5 28/05/2010 16:45

12.30 – 17.00 One-to-One Partnering Meetings.

One-to-One partnering meetings will run alongside the conference sessions. Choose which conference sessions you would like to attend and build your personalised meeting agenda around your availability accordingly.

08.15 Registration and Co� ee08.50 Chairman’s welcome

09.00to

12.00

NEW FOR 2010! Early-Stage WorkshopNew for 2010 and by popular demand, we bring you an exclusive, interactive forum for biotechs and big pharma involved in early-stage deals to come together and develop strategies to overcome top challenges. The workshop will consist of interactive roundtable discussions as well as practical hands-on insight giving you the opportunity to address key topics, including:• Identifying strategies for survival and growth• Funding opportunities for early stage biotechs: what are the options of fi nancial backing and the

advantages and disadvantages of these opportunities?• Exploring suitable partners to drive scientifi c ideas from discovery research to clinical stage testing and market approval• Breaking down recent early-stage deals: what works and what doesn’t• An analysis of high-profi le early stage deal case studies• Improving strategic planning to balance risk with rewardTo ensure participants have maximum opportunity for interaction and benefi cial discussion, places are strictly limited. To register your place, contact the conference organisers at [email protected].

09.00 Case Study: The Acquisition Of Novexel By AstraZeneca Olivier Litzka, Partner, Edmond de Rothschild Investment Partners Iain Buchanan, CEO, Novexel Karen Gallant, Business Development Director, Infection in Strategic

Partnering and Business Development, AstraZeneca• Context of the anti-infective market and the need for novel approaches• Company profi le in anti-infectives: Novexel and AstraZeneca• Assessing the strategic rationale for M&A and the structure of the transaction• The outcome: success factors and lessons learned

09.30 Panel Discussion - BioPharma Focus: What Can Big Pharma Learn From The Biotech World?

Roland Kozlowski, CEO, Lectus Therapeutics Paula Zeilon, CEO, Alligator BioScience Kees Lucas, Managing Director, Life Science Consultancy Kim Koh Bill, Vice-President, Corporate Development, Debiopharm

• Balancing the innovation and entrepreneurship of biotechs with the structure and organisation of big pharma

• Advantages of being big (fi nancial strength and organisation resilience) versus the inhibitors (bureaucracy and infl exibility)

• Can you be big and small at once?• Bridging the communication gap between pharma and biotech companies• How can deal-making be improved if pharma learn a lesson or two from their biotech partners?

10.00 Case Study: Merck & Co. Entering The German Chemical Space - An Overview Of The Deal With Elexopharm

Dr Manfred Horst, Director Scienti� c Liaison, France and Germany, Merck & Co

10.30 Panel Discussion: The Emergence And Growth Of Corporate VCs – Understanding The Issues And Evaluating The Players

Roel Bulthuis, Head – Merck Serono Ventures Graziano Seghezzi, Partner, So� nnova Partners Alan Warrander, Director, Warrander Consulting

• The increasing prominence of big pharma in funding early-stage drug discovery and development: strategic objectives and compensation structures

• Avoiding the risks associated with long-term partnerships and licensing deals• Outlining the challenges and opportunities for biotechs: from funding to investment policies• Does the growth in CVCs inhibit future partnering prospects or will they rise to the challenge?• Assessing the pros and cons from the perspective of biotechs

11.00 Morning Co� ee

11.30 Panel Discussion: Is the Partnering Paradigm Alive And Well?

Magnus Bjorsne, Business Development Director, AstraZeneca Jeremy Carmichael, Head of Business Development, Astex Nigel Sheail, Global Head of Licensing, Roche Katherine Cohen, Global Head of Corporate & Business Development,

Intercell Gary Deeb, VP of Global Licensing & Business Development,

Glenmark Pharmaceuticals Carlos De Sousa, Vice-President Corporate Licensing, Nycomed

• Is the age of doing a deal and retaining partnering over in the pursuit for fast bucks?• Is partnering the sole customer or is there the game of building new companies?• What does the future look like for partnering and how do you need to adapt?

12.00 Panel Discussion: Exploring New And Alternative Models To Enhance Future R&D Collaboration

Darren Ji, CEO, PharmaLegacy Laboratories Jay Maden, Vice President, Business Development

Biopharmaceuticals, Reliance Life Sciences Benedikt Timmerman, CEO, GENTICEL Kees Been, CEO, Envivo Pharmaceuticals

• Which R&D developments and innovative new treatments will expand the pharma biotech market?

• Key ways to cost-eff ectively and innovatively increase R&D capabilities and secure new R&D partnerships

• Who is responsible for driving R&D collaboration and how are such partnerships structured?• Evaluating the latest technologies to drive R&D innovation and ensure long term industry

sustainment• Solving the pre-clinical translation problem

12.30 Pharma/Biotech M&A – Exclusive Preview Of The New HBM Report

Chandra Leo, Partner, HBM CapitalThe new M&A environment has been created by recent changes in the pharmaceutical landscape, public markets and private fi nancings. In this session, HBM Partners analyses the latest trends in pharma/biotech trade sales from around the world. • How are the number and volume of M&A deals evolving?• Who are the most active buyers and what are their deal terms? • And which companies are today’s hottest acquisition targets?

12.45 Investment Challenge – Awards and Feedback

13.00 Networking Lunch

14.00 Modern Day Pharma Collaborations – The Open Innovation Approach

Peter Luke, Senior Director, Strategic Alliances, P� zer

14.30 Biotech Focus: Top Tips To Raise Capital In A Changing World

Jason Slingsby, CEO, ProtA� n Biotechnologie• How to avoid a funding crisis: what you need to know• Evaluating your investment needs based on size and stage of development• Exploring the options: from venture capitalists to academic grants and angel investors• Adapting your proposition based on market conditions and project needs

15.00 Harnessing Academia-Industry Partnerships To Drive Drug Discovery

Laura MacDonald, Head of Licensing, LURIS, University of Leiden• Successful collaboration: tried and tested models “’versus”” new innovative partnerships• Tried and tested models : new technologies taken forward - rare diseases and rheumatoid arthritis• Innovative models for collaboration: risk sharing and expertise pooling across public

sector and industry

15.30 Afternoon Tea

16.00 Evaluating New Projects And Opportunities From The Perspective Of A Biotech

Manfred Groeppel, Business Development Director, 4SC• Valuation tools: an overview of useful gears• The aspects and relevance of input data: success rates, duration, DCF, peak sales etc. • Examples and what can we learn from the rNPV of a project?

16.30 Case Study: Antisense + SiRNA Therapeutics: A Turbulent Past, A Bright Future

Elias Papatheodorou, CEO, Novosom• A review of the developments of the last 5 years• Major roadblocks: what challenges have been overcome and what can we still expect?• Current programmes in the clinic• Future directions and strategic goals

17.00 Chairman’s Summary and End of Conference

MAIN CONFERENCE DAY TWO 30th September 201008.15 Registration and Co� ee 12.00 Panel Discussion: Exploring New And Alternative

MAIN CONFERENCE DAY TWO 30th September 2010



6133 AW.indd 6 28/05/2010 16:46

“ We thoroughly enjoyed the eye-opening seminars. BioBusiness allows a more intimate, honest and constructive exchange of opinions than other conferences”

Rami Suzuki, Senior Manger, Oncology, Corporate Business Development, Eisai

“ I attend many conferences in my role at GSK, but I certainly found this event to be of very high quality and extremely useful ”Kate Burt, Director, Commercial Alliances and Transactions, Worldwide Business Development, GlaxoSmithKline

“ This was a meeting of the right size and focus to put together industry representatives with common goals and to allow su� cient time and space to have meaningful discussions. It was also well-coordinated ”

Kay Wagoner, CEO, Icagen

“ A very successful event for me, both the informal and formal networking is outstanding ”Christine Lemke, VP Business Development, Medigene

“ The size and exclusivity of the audience at BioBusiness make it an extremely productive Bio-partnering event ”Margaret Beer, Scienti� c Liason, Merck

Hear What Your Peers Have To Say About BioBusiness Network 2010:

Take Home The BioBusiness Network CD Rom

Just Some Of The CompaniesThat Have Attended Biobusiness Network Include:

BT PharmaCambridge Theranostics LtdCaprion Pharmaceuticals IncCDC InnovationCelgeneCellzome IncCerbios-Pharma SACerimon PharmaceuticalsCEVEC Pharmaceuticals GmbHChemical Diversity Labs, Inc.ChimaerabioChroma Therapeutics LtdCLARA - Cancéropôle Lyon Auvergne Rhône-AlpesCMS Cameron McKannaCompugenCoulter PartnersCubist PharmaceuticalsCyprotex DiscoveryCzech InvestDafra Pharma InternationalDebiopharmDyax CorpEisai Europe Limited

ElanElchromEli LillyEnzon PharmaceuticalsEquateqERYtech PharmaEvotecF. Ho� mann-La Roche LtdForest Laboratories IncGalantos PharmaGlaxoSmithKlineGlycotope GmbHHBM BioVentures LtdHybrigenicsHyglos GmbHIDISImmunehealthIndex VenturesIntercell AGJado TechnologiesJanssen Cilag LtdJohnson & JohnsonKempen & CoKenta Biotech Ltd

LifeCycle Pharma A/SMC2 BiotekMerck KGaAMerck SeronoMerLionMerrion BioPharma Ltd..MicrometMMI GroupModern BiosciencesNeovacs SANeumann InternationalNeurim PharmaceuticalsNotox B.VNovartis Horsham Research CentreNovo Nordisk ASNovozymes A/SPaion Deutschland GmbHPeakdale Molecular LtdP� zer LimitedPharmalink ABPolyTherics LtdProbiodrug AGProcter & Gamble Proteros

Rhein BiotechSano� -AventisSantaris PharmaScottish BiomedicalScynexisSelcia Ltd.Seventure PartnersSolvay Pharmaceuticals GmbhStaatzSymphogen ASSynosia TherapeuticsSyntaxin LtdTakeda Global R&D CentreTechnoPhage SATeva Pharmaceutical Industries LtdTheratechnologies inc.Transgene SATransperfect Life Sciences PracticeTVM CapitalVentechVIBVifor Pharma Ltd.Xplico A/S

At this year’s event we will be recording the presentations, discussions and debates on CD Rom so that you don’t miss out on any of the action while

you take part in your one-to-one partnering meetings. Capture all the detail of the sessions and learn at your own pace when you get back to the o� ce.

For details, see the back page

Group Savings!

2 delegates – save 15% 3 delegates – save 20% +4 delegates – save 25%

Bring your teams and take advantage of our tremendous savings:

Group discounts do not apply to sponsoring or exhibiting companies. Please note that no two discounts can be combined. To qualify for the discount, the entire group must be booked and paid for at the same time.

Just Some Of The CompaniesThat Have Attended Biobusiness Network Include:



6133 AW.indd 7 28/05/2010 16:46

About Our Sponsors:

Media Partners:

BioAlps, the fastest growing life science cluster in the world. BioAlps, the Western Switzerland life science cluster, is rated the third European centre for research into biotechnology and medical technologies after Cambridge and Oxford in the United Kingdom. It covers more than 700 biotech and medtech companies, 500 research laboratories, some 20 world-famous research institutions, universities and university hospitals, as well as numerous bodies supporting innovation including science parks, incubators of start-up companies and venture capital funds. Above all, it is a centre of excellence which attracts many famous scientists. This stems as much from its dynamic nature as from its resources in research and development and its dense industrial fabric, which o� er so many opportunities. www.bioalps.org

Supported by:

Elan Drug Technologies, the world’s leading drug delivery business delivers clinically meaningful bene� ts to patients, by using their extensive experience and proprietary delivery technologies in partnership with pharmaceutical companies, to develop new and innovative products. From bioavailability enhancement technologies for poorly water soluble compounds, to customised oral drug technologies, they o� er our clients unrivalled drug delivery expertise with a suite of commercially launched, proprietary, technology-driven solutions. With 40 years experience in the drug delivery business, they have successfully brought 36 drugs to market for clients in over 100 markets worldwide. They also have extensive product development, scale-up and manufacturing capabilities in the US and EU with over 500,000 sq ft of FDA/EMEA licensed facilities under roof and the capacity to manufacture over 2.5 billion solid oral dosages annually. Products enabled by their technologies are used by millions of patients each day. More information is available at www.elandrugtechnologies.com

Merck Serono is the division for innovative prescription pharmaceuticals of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. In the United States and Canada, EMD Serono operates through separately incorporated a� liates. Merck Serono has leading brands serving patients with cancer (Erbitux®, cetuximab), multiple sclerosis (Rebif®, interferon beta-1a), infertility (Gonal-f®, follitropin alfa), endocrine and metabolic disorders (Saizen® and Serostim®, somatropin), (Kuvan®, sapropterin dihydrochloride) as well as cardiometabolic diseases (Glucophage®, metformin), (Concor®, bisoprolol), (Euthyrox®, levothyroxine). Not all products are available in all markets. With an annual R&D expenditure of over € 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and in� ammatory diseases. For more information, please visit www.merckserono.com or www.merck.de

Nycomed is a privately owned global pharmaceutical company with a di� erentiated portfolio focused on branded medicines in gastroenterology, respiratory and in� ammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. Its R&D is built to be open for partnerships as in-licensing is a cornerstone of the company’s growth strategy. Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed will further strengthen its position in key Asian markets. Headquartered in Zurich, Switzerland, the company generated in 2009 total sales of €3.2 billion and an adjusted EBITDA of €1.075 billion.

Teva Pharmaceuticals one of the world’s top 20 pharmaceutical companies and is the leader in generic pharmaceuticals. Teva also has proprietary (or innovative) pharmaceuticals on the market and has a strong pipeline of innovative projects in clinical development. Teva Innovative Ventures is seeking to increase further this Innovative pipeline by partnering or licensing pre-clinical programs via our � exible partnership models. We are looking for therapies for CNS disorders (with emphasis on multiple sclerosis), autoimmune diseases, in� ammatory diseases and oncology. Our key criteria are that the opportunities are at a development stage between lead molecule and � rst-in-man dosing, have strong IP, meet a clear unmet medical need and that they can show diff erentiation from current clinical care. We source novel programs from University groups, spin-out or start-up companies, and from smaller Biotech. We aim to rapidly develop our partners’ innovative therapies through our global development organisation, and make them available for patients. Teva currently operates in over 60 countries and has around 35,000 employees worldwide.

O� cial PR partner

Merck & Co., Inc., is an innovative, global health care leader that is committed to improving health and well-being around the world. Merck discovers, develops, manufactures, and markets vaccines, medicines, and consumer and animal health products designed to help save and improve lives. The recent merger of Merck and Schering-Plough greatly expands our combined company’s product o� erings in a range of areas, including heart and respiratory health, infectious diseases, and women’s health. We continue to focus our research on conditions that a� ect millions of people around the world — diseases such as Alzheimer’s, diabetes, and cancer — while expanding our strengths in areas like vaccines and biologics. Merck invests heavily in research and development. Our strategy for growth is based on breakthrough research — both internal and external through partnerships — and demonstrating the value of our medicines to patients, payers, and providers. At today’s Merck, we’re applying our global reach, � nancial strength and scienti� c excellence to do more of what we’re passionate about: improving health and improving lives. Merck is strongly committed to partnership success. For all the original research we conduct, we know that the next great discovery in medicine may well come from outside of our laboratories. This is why the formation of strategic partnerships is a central part of our business and research strategy. For further information, please visit our Web site at http://www.merck.com/licensing/



6133 AW.indd 8 28/05/2010 16:46

3. YES! I wish to register for BioBusiness Network 2010Your information will be held and used by Worldwide Business Research Limited (“WBR”) to register you for this conference and/or we may contact you by email, phone or post with information about other conferences, products and services, which our associated companies or we provide. We may also from time to time share your information with other parties in the European Economic Area who may wish to contact you by phone or post, in relation to special o� ers, products and services related to your role within your company. If you would prefer not to receive such information from us or such third parties, please fax us, including a copy of this page, on UK free phone fax number 0800 652 5943 or +44 20 7368 9401

PAYMENT DETAILS:Payment should be received by WBR Ltd within 7 days of the invoice date or by expiry of given discount date whichever is earliest. If payment is not received by the o� ered discount date the higher price will apply. Any booking made in the 14 days prior to the conference must be paid by credit card.

Payment of invoices other than by means of credit cards or purchase order (UK PLC and Government bodies only) will be subject to a £49 (plus VAT) processing fee

Please charge my AMEX/VISA/MASTERCARD (please delete as applicable)

Card no . ...................................................................................................................................................................................................... Security Code. ................................................ Expiry Date. ..................................................

Cardholder’s Name ............................................................................................................................................................. Cardholder’s Signature ..............................................................................................................................

or I will be sending a bank transfer to Worldwide Business Research Ltd’s bank: HSBC, 79 Piccadilly, London W1J 8EU.

GBP payments to be made to: A/C No: 21243578, Sort Code: 40-05-26, IBAN: GB09MIDL40052621243578, BIC: MIDLGB2107L.

Please fax con� rmation of the bank transfer to Credit Control on +44 (0)20 7368 9401, quoting delegate’s name and booking code 11230.004 as your reference on both fax and bank transfer

or I enclose a cheque made payable to WBR LtdWBR Ltd Cancellation, Postponement and Substitution Policy: You may substitute delegates at any time by providing reasonable advance notice to WBR. For any cancellations received in writing not less than twenty two (22) days prior to the conference, you will receive a 90% credit to be used at another WBR Ltd conference which must occur within one year from the date of issuance of such credit. An administration fee of 10% of the contract fee will be retained by WBR Ltd for all permitted cancellations. No credit will be issued for any cancellations occurring within twenty one (21) days (inclusive) of the conference. In the event that WBR Ltd cancels an event for any reason, you will receive a credit for 100% of the contract fee paid. You may use this credit for another WBR Ltd event to be mutually agreed with WBR Ltd, which must occur within one year from the date of cancellation. In the event that WBR Ltd postpones an event for any reason and the delegate is unable or unwilling to attend in on the rescheduled date, you will receive a credit for 100% of the contract fee paid. You may use this credit for another WBR Ltd event to be mutually agreed with WBR Ltd, which must occur within one year from the date of postponement. Except as specifi ed above, no credits will be issued for cancellations. There are no refunds given under any circumstances. WBR Ltd is not responsible for any loss or damage as a result of a substitution, alteration or cancellation/postponement of an event. WBR Ltd shall assume no liability whatsoever in the event this conference is cancelled, rescheduled or postponed due to a fortuitous event, Act of God, unforeseen occurrence or any other event that renders performance of this conference impracticable, illegal or impossible. For purposes of this clause, a fortuitous event shall include, but not be limited to: war, fi re, labor strike, extreme weather or other emergency. Please note that while speakers and topics were confi rmed at the time of publishing, circumstances beyond the control of the organizers may necessitate substitutions, alterations or cancellations of the speakers and/or topics. As such, WBR Ltd reserves the right to alter or modify the advertised speakers and/or topics if necessary without any liability to you whatsoever. Any substitutions or alterations will be updated on our web page as soon as possible.

1. Delegate Details

Surname (Mr/Mrs/Ms) ..................................................................................................................................

Name ......................................................................................................................................................................

Job Title .................................................................................................................................................................

Department........................................................................................................................................................

Head of Department ....................................................................................................................................

Registration Contact .....................................................................................................................................

Company..............................................................................................................................................................

Address ..................................................................................................................................................................

....................................................................................................................................................................................

....................................................................................................................................................................................

City ...........................................................................................................................................................................

Post Code .............................................................................................................................................................

Country .................................................................................................................................................................

Email (required) ................................................................................................................................................

Tel..............................................................................................................................................................................

Fax ............................................................................................................................................................................

Company VAT No. ...........................................................................................................................................

2. Registration Options (please tick)

Biotech & Big Pharma

Bookings received by Friday 25th June

Bookings received by Friday 30th July Final Price

Conference Only £1579 £1679 £1779

Conference + Company Profi le

£1978 £2078 £2178

CD Rom £299

Others

Bookings received by Friday 25th June

Bookings received by Friday 30th July Final Price

Conference Only £2199 £2299 £2399

Conference + Company Profi le

£2598 £2698 £2798

CD Rom £299

*All prices are subject to 7.6% Swiss VAT

Fax back on +44 (0)20 7368 9401Alternatively please mail to:BioBusiness Network 2010, WBR Ltd, Anchor House, 15-19 Britten Street, London, SW3 3QL, United Kingdom.Or email [email protected] Tel: +44 (0)20 7368 9465 Web: www.biobusinessnetwork.com

Booking Ref:

BioBusiness Network 2010 29th – 30th September 2010, Intercontinental Hotel, Geneva www.biobusinessnetwork.com

6133 AW.indd 1 28/05/2010 16:46